Concepts (252)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Analgesics, Opioid | 7 | 2025 | 251 | 1.500 |
Why?
|
| Opioid-Related Disorders | 7 | 2025 | 68 | 1.350 |
Why?
|
| Bayes Theorem | 10 | 2025 | 83 | 1.100 |
Why?
|
| Community-Based Participatory Research | 2 | 2025 | 114 | 0.810 |
Why?
|
| Ohio | 8 | 2025 | 63 | 0.800 |
Why?
|
| Humans | 50 | 2026 | 32284 | 0.690 |
Why?
|
| Decision Making | 1 | 2023 | 190 | 0.660 |
Why?
|
| Adult | 24 | 2026 | 9263 | 0.620 |
Why?
|
| Patient Admission | 2 | 2019 | 54 | 0.610 |
Why?
|
| Sexually Transmitted Diseases | 3 | 2025 | 51 | 0.590 |
Why?
|
| HIV Infections | 4 | 2025 | 451 | 0.580 |
Why?
|
| Research Design | 2 | 2023 | 316 | 0.570 |
Why?
|
| Population Surveillance | 1 | 2019 | 120 | 0.550 |
Why?
|
| Male | 36 | 2026 | 19434 | 0.550 |
Why?
|
| Female | 36 | 2026 | 19954 | 0.540 |
Why?
|
| Middle Aged | 22 | 2026 | 11843 | 0.470 |
Why?
|
| Hepatitis C | 3 | 2025 | 49 | 0.460 |
Why?
|
| Adolescent | 12 | 2025 | 3521 | 0.460 |
Why?
|
| Pharmacies | 2 | 2026 | 17 | 0.460 |
Why?
|
| Naloxone | 2 | 2026 | 32 | 0.460 |
Why?
|
| Narcotic Antagonists | 2 | 2026 | 47 | 0.450 |
Why?
|
| Data Collection | 1 | 2015 | 171 | 0.440 |
Why?
|
| Diabetes Mellitus | 4 | 2022 | 390 | 0.440 |
Why?
|
| Young Adult | 11 | 2025 | 2652 | 0.410 |
Why?
|
| Rural Population | 2 | 2025 | 217 | 0.390 |
Why?
|
| Fever | 2 | 2026 | 60 | 0.380 |
Why?
|
| Substance-Related Disorders | 2 | 2024 | 140 | 0.380 |
Why?
|
| United States | 8 | 2026 | 4079 | 0.370 |
Why?
|
| Appalachian Region | 4 | 2025 | 23 | 0.370 |
Why?
|
| Coronary Disease | 3 | 2022 | 226 | 0.330 |
Why?
|
| Hydrocortisone | 2 | 2021 | 64 | 0.320 |
Why?
|
| Length of Stay | 3 | 2019 | 321 | 0.300 |
Why?
|
| Aged | 16 | 2026 | 10257 | 0.300 |
Why?
|
| Blood Glucose | 3 | 2020 | 484 | 0.290 |
Why?
|
| Upper Extremity | 2 | 2019 | 68 | 0.280 |
Why?
|
| Telemedicine | 3 | 2025 | 122 | 0.280 |
Why?
|
| Bacterial Infections | 2 | 2018 | 44 | 0.260 |
Why?
|
| Prevalence | 4 | 2024 | 960 | 0.250 |
Why?
|
| Homosexuality, Male | 2 | 2025 | 115 | 0.250 |
Why?
|
| Oral Ulcer | 1 | 2026 | 6 | 0.250 |
Why?
|
| Fever of Unknown Origin | 1 | 2026 | 11 | 0.240 |
Why?
|
| Nonprescription Drugs | 1 | 2026 | 18 | 0.240 |
Why?
|
| Emergency Service, Hospital | 3 | 2019 | 444 | 0.240 |
Why?
|
| Stroke | 3 | 2022 | 691 | 0.240 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2026 | 106 | 0.230 |
Why?
|
| Licensure | 1 | 2025 | 7 | 0.220 |
Why?
|
| Automobile Driving | 1 | 2025 | 25 | 0.220 |
Why?
|
| Peer Group | 1 | 2025 | 47 | 0.220 |
Why?
|
| African Americans | 3 | 2021 | 1335 | 0.220 |
Why?
|
| Urban Population | 1 | 2025 | 91 | 0.210 |
Why?
|
| Heroin | 1 | 2024 | 33 | 0.210 |
Why?
|
| Health Services Accessibility | 1 | 2026 | 242 | 0.200 |
Why?
|
| Placenta | 1 | 2024 | 74 | 0.200 |
Why?
|
| Prospective Studies | 7 | 2026 | 2320 | 0.200 |
Why?
|
| Physicians | 1 | 2025 | 163 | 0.190 |
Why?
|
| Cohort Studies | 6 | 2026 | 1840 | 0.190 |
Why?
|
| Accidents, Traffic | 1 | 2025 | 204 | 0.190 |
Why?
|
| Age Factors | 6 | 2025 | 1179 | 0.180 |
Why?
|
| Health Status Disparities | 1 | 2024 | 128 | 0.180 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2024 | 896 | 0.180 |
Why?
|
| Hospitals, Pediatric | 2 | 2019 | 48 | 0.180 |
Why?
|
| Seroepidemiologic Studies | 1 | 2021 | 10 | 0.170 |
Why?
|
| Retrospective Studies | 8 | 2020 | 3612 | 0.170 |
Why?
|
| Child | 7 | 2020 | 2446 | 0.160 |
Why?
|
| Prognosis | 3 | 2019 | 1529 | 0.160 |
Why?
|
| Advance Care Planning | 1 | 2020 | 15 | 0.150 |
Why?
|
| Video Games | 1 | 2019 | 5 | 0.150 |
Why?
|
| Cerebrospinal Fluid Proteins | 1 | 2019 | 4 | 0.150 |
Why?
|
| Acute Disease | 2 | 2018 | 253 | 0.150 |
Why?
|
| Guillain-Barre Syndrome | 1 | 2019 | 7 | 0.150 |
Why?
|
| Insulin Resistance | 1 | 2022 | 457 | 0.150 |
Why?
|
| Adiposity | 1 | 2021 | 190 | 0.150 |
Why?
|
| Allostasis | 1 | 2019 | 12 | 0.150 |
Why?
|
| Capital Punishment | 1 | 2019 | 1 | 0.150 |
Why?
|
| Aldosterone | 1 | 2019 | 26 | 0.150 |
Why?
|
| Deep Brain Stimulation | 1 | 2019 | 52 | 0.150 |
Why?
|
| Suicide, Attempted | 1 | 2019 | 33 | 0.140 |
Why?
|
| Off-Label Use | 1 | 2019 | 14 | 0.140 |
Why?
|
| Sodium Channel Blockers | 1 | 2018 | 7 | 0.140 |
Why?
|
| Myotonic Disorders | 1 | 2018 | 3 | 0.140 |
Why?
|
| Anaphylaxis | 1 | 2019 | 12 | 0.140 |
Why?
|
| Lethargy | 1 | 2018 | 2 | 0.140 |
Why?
|
| Methicillin Resistance | 1 | 2019 | 24 | 0.140 |
Why?
|
| Consciousness Disorders | 1 | 2018 | 5 | 0.140 |
Why?
|
| Charcot-Marie-Tooth Disease | 1 | 2018 | 8 | 0.140 |
Why?
|
| Exercise Movement Techniques | 1 | 2018 | 2 | 0.140 |
Why?
|
| Nervous System Diseases | 1 | 2019 | 46 | 0.140 |
Why?
|
| Muscular Diseases | 1 | 2018 | 23 | 0.140 |
Why?
|
| Staphylococcus aureus | 1 | 2019 | 55 | 0.140 |
Why?
|
| Child Abuse | 1 | 2019 | 27 | 0.140 |
Why?
|
| Foot | 1 | 2018 | 40 | 0.140 |
Why?
|
| Lymphoma, T-Cell, Cutaneous | 1 | 2018 | 4 | 0.140 |
Why?
|
| Paresis | 1 | 2018 | 18 | 0.140 |
Why?
|
| Child, Preschool | 5 | 2019 | 1248 | 0.140 |
Why?
|
| Polymerase Chain Reaction | 1 | 2019 | 189 | 0.140 |
Why?
|
| Motor Neurons | 1 | 2018 | 50 | 0.140 |
Why?
|
| Killer Cells, Natural | 1 | 2018 | 21 | 0.140 |
Why?
|
| Office Visits | 1 | 2019 | 71 | 0.140 |
Why?
|
| Pediatrics | 1 | 2020 | 157 | 0.140 |
Why?
|
| Parkinson Disease | 1 | 2019 | 87 | 0.140 |
Why?
|
| Staphylococcal Infections | 1 | 2019 | 78 | 0.140 |
Why?
|
| Longitudinal Studies | 4 | 2022 | 760 | 0.140 |
Why?
|
| Exercise Test | 1 | 2019 | 218 | 0.130 |
Why?
|
| Heart Diseases | 1 | 2019 | 114 | 0.130 |
Why?
|
| Polyradiculoneuropathy, Chronic Inflammatory Demyelinating | 1 | 2017 | 6 | 0.130 |
Why?
|
| Muscle Contraction | 1 | 2018 | 175 | 0.130 |
Why?
|
| Dermatomyositis | 1 | 2017 | 18 | 0.130 |
Why?
|
| Myasthenia Gravis | 1 | 2017 | 15 | 0.130 |
Why?
|
| Myotonia Congenita | 1 | 2017 | 2 | 0.130 |
Why?
|
| Residence Characteristics | 1 | 2019 | 179 | 0.130 |
Why?
|
| Cardiovascular Agents | 1 | 2017 | 17 | 0.130 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2017 | 42 | 0.130 |
Why?
|
| Emergency Medical Services | 1 | 2019 | 183 | 0.120 |
Why?
|
| Atherosclerosis | 1 | 2022 | 806 | 0.120 |
Why?
|
| Depression | 1 | 2019 | 427 | 0.120 |
Why?
|
| Antihypertensive Agents | 1 | 2019 | 364 | 0.120 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 2017 | 211 | 0.110 |
Why?
|
| Data Interpretation, Statistical | 1 | 2015 | 116 | 0.110 |
Why?
|
| Time Factors | 3 | 2019 | 2196 | 0.110 |
Why?
|
| Cross-Sectional Studies | 3 | 2026 | 1485 | 0.110 |
Why?
|
| Muscle, Skeletal | 1 | 2018 | 520 | 0.100 |
Why?
|
| Ribonucleases | 1 | 2012 | 7 | 0.090 |
Why?
|
| Proteus mirabilis | 1 | 2012 | 2 | 0.090 |
Why?
|
| Quality of Life | 1 | 2018 | 971 | 0.090 |
Why?
|
| Uropathogenic Escherichia coli | 1 | 2012 | 6 | 0.090 |
Why?
|
| Anti-Infective Agents | 1 | 2012 | 35 | 0.090 |
Why?
|
| Organogenesis | 1 | 2012 | 18 | 0.090 |
Why?
|
| Infant | 3 | 2019 | 1024 | 0.090 |
Why?
|
| Skin Tests | 1 | 2011 | 13 | 0.080 |
Why?
|
| Risk Factors | 4 | 2019 | 3938 | 0.080 |
Why?
|
| Hypersensitivity | 1 | 2011 | 24 | 0.080 |
Why?
|
| Cardiovascular Diseases | 1 | 2019 | 1159 | 0.080 |
Why?
|
| Severity of Illness Index | 3 | 2018 | 851 | 0.080 |
Why?
|
| Urinary Bladder | 1 | 2012 | 320 | 0.070 |
Why?
|
| Accidental Falls | 2 | 2019 | 104 | 0.070 |
Why?
|
| Disease Models, Animal | 2 | 2024 | 1073 | 0.070 |
Why?
|
| Electromyography | 2 | 2018 | 67 | 0.070 |
Why?
|
| Hand Strength | 2 | 2018 | 98 | 0.070 |
Why?
|
| Respiratory Tract Infections | 2 | 2018 | 40 | 0.070 |
Why?
|
| Urinary Tract Infections | 2 | 2018 | 42 | 0.070 |
Why?
|
| Sex Factors | 2 | 2019 | 656 | 0.060 |
Why?
|
| Multivariate Analysis | 2 | 2019 | 650 | 0.060 |
Why?
|
| Stomatitis | 1 | 2026 | 19 | 0.060 |
Why?
|
| Transplantation Conditioning | 1 | 2026 | 23 | 0.060 |
Why?
|
| Pilot Projects | 2 | 2018 | 554 | 0.060 |
Why?
|
| Microbial Sensitivity Tests | 2 | 2019 | 81 | 0.060 |
Why?
|
| Animals | 4 | 2024 | 8165 | 0.060 |
Why?
|
| Incidence | 2 | 2019 | 1244 | 0.060 |
Why?
|
| Tissue Adhesions | 1 | 2024 | 11 | 0.050 |
Why?
|
| Drug Users | 1 | 2024 | 15 | 0.050 |
Why?
|
| Hyaluronic Acid | 1 | 2024 | 51 | 0.050 |
Why?
|
| Aged, 80 and over | 3 | 2019 | 3896 | 0.050 |
Why?
|
| Random Allocation | 1 | 2024 | 246 | 0.050 |
Why?
|
| Central Nervous System Stimulants | 1 | 2024 | 82 | 0.050 |
Why?
|
| Massachusetts | 1 | 2023 | 27 | 0.050 |
Why?
|
| Models, Statistical | 1 | 2024 | 187 | 0.050 |
Why?
|
| Medicare | 1 | 2025 | 218 | 0.050 |
Why?
|
| Follow-Up Studies | 2 | 2019 | 2238 | 0.050 |
Why?
|
| Stem Cell Transplantation | 1 | 2024 | 219 | 0.050 |
Why?
|
| Sexual Behavior | 1 | 2023 | 132 | 0.050 |
Why?
|
| Feasibility Studies | 1 | 2023 | 309 | 0.050 |
Why?
|
| Reproducibility of Results | 2 | 2017 | 755 | 0.050 |
Why?
|
| Parathyroid Hormone | 1 | 2022 | 45 | 0.050 |
Why?
|
| Vitamins | 1 | 2022 | 70 | 0.040 |
Why?
|
| Glucose | 1 | 2022 | 158 | 0.040 |
Why?
|
| Pregnancy | 1 | 2024 | 963 | 0.040 |
Why?
|
| North Carolina | 1 | 2024 | 1299 | 0.040 |
Why?
|
| Vitamin D | 1 | 2022 | 186 | 0.040 |
Why?
|
| Waist Circumference | 1 | 2021 | 91 | 0.040 |
Why?
|
| Intra-Abdominal Fat | 1 | 2021 | 58 | 0.040 |
Why?
|
| Adiponectin | 1 | 2021 | 93 | 0.040 |
Why?
|
| Rats | 1 | 2024 | 1892 | 0.040 |
Why?
|
| Glucose Intolerance | 1 | 2020 | 40 | 0.040 |
Why?
|
| Saliva | 1 | 2020 | 41 | 0.040 |
Why?
|
| Algorithms | 1 | 2023 | 537 | 0.040 |
Why?
|
| Fasting | 1 | 2020 | 88 | 0.040 |
Why?
|
| Circadian Rhythm | 1 | 2020 | 48 | 0.040 |
Why?
|
| Mice | 2 | 2018 | 2544 | 0.040 |
Why?
|
| Hemiplegia | 1 | 2019 | 10 | 0.040 |
Why?
|
| Documentation | 1 | 2020 | 39 | 0.040 |
Why?
|
| Treatment Outcome | 2 | 2017 | 3410 | 0.040 |
Why?
|
| Glasgow Coma Scale | 1 | 2019 | 26 | 0.040 |
Why?
|
| Mississippi | 1 | 2019 | 38 | 0.040 |
Why?
|
| Respiration, Artificial | 1 | 2019 | 98 | 0.040 |
Why?
|
| Emergency Medical Service Communication Systems | 1 | 2019 | 2 | 0.040 |
Why?
|
| Stiff-Person Syndrome | 1 | 2018 | 1 | 0.040 |
Why?
|
| DNA, Bacterial | 1 | 2019 | 35 | 0.040 |
Why?
|
| Myelin Proteins | 1 | 2018 | 4 | 0.040 |
Why?
|
| Toes | 1 | 2018 | 13 | 0.040 |
Why?
|
| Torque | 1 | 2018 | 21 | 0.040 |
Why?
|
| Superoxide Dismutase | 1 | 2018 | 41 | 0.040 |
Why?
|
| Muscle Weakness | 1 | 2018 | 34 | 0.040 |
Why?
|
| Observer Variation | 1 | 2019 | 96 | 0.040 |
Why?
|
| K562 Cells | 1 | 2018 | 3 | 0.040 |
Why?
|
| Gastroenteritis | 1 | 2018 | 15 | 0.040 |
Why?
|
| Disability Evaluation | 1 | 2019 | 241 | 0.040 |
Why?
|
| Regression Analysis | 1 | 2019 | 273 | 0.030 |
Why?
|
| Chronic Disease | 1 | 2020 | 411 | 0.030 |
Why?
|
| Neuromuscular Junction | 1 | 2018 | 70 | 0.030 |
Why?
|
| Amyotrophic Lateral Sclerosis | 1 | 2018 | 58 | 0.030 |
Why?
|
| Bacterial Proteins | 1 | 2019 | 99 | 0.030 |
Why?
|
| Triage | 1 | 2019 | 68 | 0.030 |
Why?
|
| Poverty | 1 | 2019 | 105 | 0.030 |
Why?
|
| Guideline Adherence | 1 | 2019 | 109 | 0.030 |
Why?
|
| Mice, Transgenic | 1 | 2018 | 254 | 0.030 |
Why?
|
| Drug Therapy, Combination | 1 | 2019 | 293 | 0.030 |
Why?
|
| Cause of Death | 1 | 2019 | 236 | 0.030 |
Why?
|
| Mortality | 1 | 2019 | 122 | 0.030 |
Why?
|
| Patient Discharge | 1 | 2019 | 204 | 0.030 |
Why?
|
| Plasmapheresis | 1 | 2017 | 11 | 0.030 |
Why?
|
| Action Potentials | 1 | 2018 | 212 | 0.030 |
Why?
|
| Autoimmunity | 1 | 2017 | 30 | 0.030 |
Why?
|
| Proportional Hazards Models | 1 | 2019 | 773 | 0.030 |
Why?
|
| Predictive Value of Tests | 1 | 2019 | 880 | 0.030 |
Why?
|
| Guidelines as Topic | 1 | 2017 | 47 | 0.030 |
Why?
|
| Diagnosis, Differential | 1 | 2018 | 502 | 0.030 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2017 | 115 | 0.030 |
Why?
|
| Poisson Distribution | 1 | 2016 | 17 | 0.030 |
Why?
|
| Disease Progression | 1 | 2018 | 590 | 0.030 |
Why?
|
| Infant, Newborn | 1 | 2019 | 674 | 0.030 |
Why?
|
| Geriatric Assessment | 1 | 2018 | 335 | 0.030 |
Why?
|
| Pain | 1 | 2018 | 303 | 0.030 |
Why?
|
| Anti-Bacterial Agents | 1 | 2019 | 336 | 0.030 |
Why?
|
| Mice, Inbred C57BL | 1 | 2018 | 776 | 0.030 |
Why?
|
| Hospital Mortality | 1 | 2017 | 197 | 0.030 |
Why?
|
| Immunosuppressive Agents | 1 | 2017 | 248 | 0.030 |
Why?
|
| Comorbidity | 1 | 2017 | 563 | 0.030 |
Why?
|
| Administration, Oral | 1 | 2016 | 201 | 0.030 |
Why?
|
| European Continental Ancestry Group | 1 | 2019 | 1076 | 0.030 |
Why?
|
| Obesity | 1 | 2022 | 1108 | 0.030 |
Why?
|
| Databases, Factual | 1 | 2016 | 368 | 0.030 |
Why?
|
| Myocardial Infarction | 1 | 2019 | 466 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2016 | 709 | 0.030 |
Why?
|
| Antimicrobial Cationic Peptides | 1 | 2012 | 13 | 0.020 |
Why?
|
| Protein Structure, Tertiary | 1 | 2012 | 113 | 0.020 |
Why?
|
| Recombinant Proteins | 1 | 2012 | 263 | 0.020 |
Why?
|
| Receptor, Fibroblast Growth Factor, Type 2 | 1 | 2012 | 5 | 0.020 |
Why?
|
| Heart Failure | 1 | 2019 | 727 | 0.020 |
Why?
|
| Mice, Mutant Strains | 1 | 2012 | 49 | 0.020 |
Why?
|
| Risk Assessment | 1 | 2017 | 1424 | 0.020 |
Why?
|
| Gene Expression | 1 | 2012 | 345 | 0.020 |
Why?
|
| Urothelium | 1 | 2012 | 64 | 0.020 |
Why?
|
| Antigens, Dermatophagoides | 1 | 2011 | 1 | 0.020 |
Why?
|
| Pyroglyphidae | 1 | 2011 | 1 | 0.020 |
Why?
|
| Trees | 1 | 2011 | 2 | 0.020 |
Why?
|
| Antigens, Plant | 1 | 2011 | 4 | 0.020 |
Why?
|
| Poaceae | 1 | 2011 | 2 | 0.020 |
Why?
|
| Organ Size | 1 | 2012 | 221 | 0.020 |
Why?
|
| Allergens | 1 | 2011 | 14 | 0.020 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2012 | 132 | 0.020 |
Why?
|
| Muscle, Smooth | 1 | 2012 | 152 | 0.020 |
Why?
|
| Peptide Fragments | 1 | 2012 | 417 | 0.020 |
Why?
|